Identifying cancer risk using digital and molecular markers
Official title: Digital and Molecular Detection of Markers for Disease Risk Prediction, Improvement of Diagnostic Detection Accuracy and Implementation for Preventive Measures of Cancer - A Combined Case-control and Cohort Study
Run by University of Erlangen-Nürnberg Medical School · NCT06962670 · Data updated 2026-11-12
This study is trying to find new ways to predict the risk of developing different types of cancer, especially breast cancer, by looking at biological markers and lifestyle factors in both cancer patients and healthy people.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 1250 (estimated) |
| Sponsor | University of Erlangen-Nürnberg Medical School Academic / other |
| Locations | 1 site (Please Refer to Project Homepage For Details (see Link Below), Bavaria) |
| Status | Recruiting |
| Started | September 14, 2024 |
| Main results expected | September 2025 |
| Study ends | December 2025 |
| Registry record updated | May 8, 2025 |
| Trial ID | NCT06962670 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adult women aged 18 and older with a current or past diagnosis of specific cancers such as breast, lung, colorectal, or gynecologic cancers.
✕Probably not a fit
Patients with known infections like HIV or active SARS-CoV2, or those with acute severe illnesses unrelated to the specified cancers, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to discover new markers that can predict the risk of developing various cancers, with a primary focus on breast cancer. Researchers will collect data from both cancer patients and healthy individuals to identify differences in biomarkers, lifestyle factors, and family history that may indicate an increased risk of cancer. Participants will use the BayPass mobile application to facilitate data collection and analysis. The study involves biomaterial collection to support the identification of these predictive markers.
Why it matters
Potential benefit: If successful, this study could lead to improved methods for early cancer detection and risk assessment.
How similar studies have gone: Other studies have shown promise in using digital and molecular markers for cancer risk prediction, making this approach both relevant and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Biological adult (at least 18 years old) women 2. Written informed consent for study participation and processing of personal data 3. Own smartphone that can run the BayPass mobile application and willingness to use said smartphone for study purposes Additional inclusion criterion for case group: 4. Pre-existing or current diagnosis of at least one of the following oncological diseases: breast cancer, lung cancer, colorectal cancer, gynecologic cancer (incl. ovarian cancer, endometrial cancer, cervical cancer, fallopian tube cancer, vaginal cancer and vulvar cancer) Exclusion Criteria: 1. Known infection with HIV (Human Immunodeficiency Virus), HepA (Hepatitis A), HepB (Hepatitis B), HepC (Hepatitis C) or active SARS-CoV2 (Severe acute respiratory syndrome coronavirus type 2) infection 2. Acute severe or potentially life-threatening illness, except those specified in inclusion criterion #4
Where it's running
-
DigiOnko Präventionsmobil
Please Refer to Project Homepage For Details (see Link Below), Bavaria, Germany Recruiting
Study contacts
- Study coordinator: Peter A. Fasching, Prof. Dr. med.
- Email: fk-digionko@uk-erlangen.de
- Phone: +49 9131 85 33572
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Riluzole to prevent thinking and memory problems during chemotherapy
This pilot trial tests whether riluzole can prevent thinking and memory problems in adults with cancer receiving anthracycline- or platinum-based chemotherapy.
-
Florida ASCENT Program
This project will test whether combining the MyCarePulse EHR platform with ASCENT patient navigators helps adults with recent cancer diagnoses in Florida improve food security, diet quality, and confidence in healthy eating compared with standard care.
-
Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues
This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
Precision navigation to boost cancer screening participation in high-risk communities
This study tests whether a personalized navigation program helps adults aged 45–74 in Chinese communities who are at high risk for several cancers to complete recommended free cancer screenings.
-
LRRC15-targeted PET imaging for more precise diagnosis and staging of pancreatic, breast, lung, sarcoma and head-and-neck cancers
This project tests whether an LRRC15-targeted PET scan can better detect and stage LRRC15-expressing cancers and measures how the tracer behaves in healthy adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.